SCY-078 + Fluconazole
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvovaginal Candidiasis
Conditions
Vulvovaginal Candidiasis
Trial Timeline
Nov 1, 2015 → Aug 5, 2016
NCT ID
NCT02679456About SCY-078 + Fluconazole
SCY-078 + Fluconazole is a phase 2 stage product being developed by Scynexis for Vulvovaginal Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02679456. Target conditions include Vulvovaginal Candidiasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02679456 | Phase 2 | Completed |
Competing Products
10 competing products in Vulvovaginal Candidiasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene Vaginal | Novo Nordisk | Phase 3 | 76 |
| Fluconazole | Pfizer | Phase 3 | 76 |
| Clotrimazole vaginal tablet + Fluconazole | Bayer | Approved | 82 |
| Ibrexafungerp | Scynexis | Phase 3 | 69 |
| Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet | Scynexis | Phase 3 | 69 |
| Ibrexafungerp | Scynexis | Phase 1 | 25 |
| Estradiol + Placebo | TherapeuticsMD | Phase 3 | 69 |
| Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB) | Matinas Biopharma | Phase 2 | 44 |